FDA sees bowel risk in early Glaxo vaccine data
WASHINGTON (Reuters) - GlaxoSmithKline Plc's rotavirus vaccine may be linked to a small increase in a life-threatening type of bowel obstruction, U.S. health officials said on Wednesday.
Early data from a study in Mexico suggested infants given the Rotarix vaccine may face a higher chance of an intestinal problem known as intussusception in the 31 days after their first dose, the Food and Drug Administration said on its website.
"Although the results are preliminary and will require further evaluation, FDA approved revised labeling to inform healthcare providers of this finding," the agency said.
Rotavirus is the world's leading cause of severe diarrhea and dehydration in young infants. The benefits of rotavirus vaccines continue to outweigh risks, the FDA said.
Glaxo's rotavirus vaccine sales in 2009 were $440 million globally, including $118 million in the United States.
The British drug company's shares slipped 0.7 percent to $40.06 in morning trading on the New York Stock Exchange.
(Reporting by Lisa Richwine; Editing by Maureen Bavdek)
- Tweet this
- Share this
- Digg this
- UPDATE 1-Boehner erupts at conservative groups ahead of U.S. budget vote
- UPDATE 2-Hawaii official who released Obama birth certificate dies in plane crash
- Republican feud boils over in U.S. budget deal fight
- US STOCKS-Wall St drops on taper anxiety; Facebook rallies
- UPDATE 2-Bank of Canada sees rates on hold 'quite some time'
While focus on the “core” communities has helped keep the disease in check, authorities must “follow the epidemic” and target internal migrants and truckers to widen the scope of prevention efforts, two UNAIDS officials said in an interview with India Insight. Article